Mepenzolate bromide displays beneficial effects in a mouse model of chronic obstructive pulmonary disease

Nature Communications

Volumn 4, Issue , 2013, Pages

  Tanaka, Ken Ichiro ^a   Ishihara, Tomoaki ^a   Sugizaki, Toshifumi ^a   Kobayashi, Daisuke ^a   Yamashita, Yasunobu ^a   Tahara, Kayoko ^a   Yamakawa, Naoki ^a   Iijima, Kumiko ^b   Mogushi, Kaoru ^b   Tanaka, Hiroshi ^b   Sato, Keizo ^c   Suzuki, Hidekazu ^d   Mizushima, Tohru ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BRONCHODILATING AGENT; CIGARETTE SMOKE; ELASTASE; MEPENZOLATE; PANCREATIC ELASTASE; SUPEROXIDE;

AIRFLOW; BROMINE COMPOUND; DISEASE TREATMENT; DRUG; ENZYME ACTIVITY; RESPIRATORY DISEASE; RODENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GASTROINTESTINAL DISEASE; MOUSE; MOUSE MODEL; NONHUMAN; RESPIRATORY FAILURE; TREATMENT DURATION;

MUS;

ADMINISTRATION, INHALATION; ANIMALS; ANIONS; ANTI-INFLAMMATORY AGENTS; BENZILATES; BRONCHOALVEOLAR LAVAGE; BRONCHODILATOR AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INFLAMMATION; INFUSIONS, PARENTERAL; LUNG; MALE; MICE; MICE, INBRED DBA; MICE, INBRED ICR; NADPH OXIDASE; NF-KAPPA B; PANCREATIC ELASTASE; PIPERIDINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; SUPEROXIDES; SWINE; TIME FACTORS;

EID: 84889250123     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3686     Document Type: Article

References (38)

1. Rabe, K. F. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care. Med. 176, 532-555 (2007).
2. Barnes, P. J. &Stockley, R. A. COPD: current therapeutic interventions and future approaches. Eur. Respir. J. 25, 1084-1106 (2005).
3. Owen, C. A. Proteinases and oxidants as targets in the treatment of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2, 373-385 discussion 394-375 (2005).
4. Tashkin, D. P. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 359, 1543-1554 (2008).
5. Calverley, P. M. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 356, 775-789 (2007).
6. Alsaeedi, A., Sin, D. D. &McAlister, F. A. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. 113, 59-65 (2002).
7. Barnes, P. J., Ito, K. &Adcock, I. M. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363, 731-733 (2004).
8. Drummond, G. R., Selemidis, S., Griendling, K. K. &Sobey, C. G. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat. Rev. Drug. Discov. 10, 453-471 (2011).
9. Gosker, H. R. et al. Altered antioxidant status in peripheral skeletal muscle of patients with COPD. Respir. Med. 99, 118-125 (2005).
10. Rahman, I. &MacNee, W. Antioxidant pharmacological therapies for COPD. Curr. Opin. Pharmacol. 12, 256-265 (2012).
11. Barnes, P. J. Role of HDAC2 in the pathophysiology of COPD. Annu. Rev. Physiol. 71, 451-464 (2009).
12. Rajendrasozhan, S., Yang, S. R., Edirisinghe, I., Yao, H., Adenuga, D. &Rahman, I. Deacetylases and NF-kappaB in redox regulation of cigarette smoke-induced lung inflammation: epigenetics in pathogenesis of COPD. Antioxid. Redox. Signal. 10, 799-811 (2008).
13. Rahman, I. &Adcock, I. M. Oxidative stress and redox regulation of lung inflammation in COPD. Eur. Respir. J. 28, 219-242 (2006).
14. Yao, H. et al. Redox regulation of lung inflammation: role of NADPH oxidase and NF-kappaB signalling. Biochem. Soc. Trans. 35, 1151-1155 (2007).
15. Yang, S. R. et al. Cigarette smoke induces proinflammatory cytokine release by activation of NF-kappaB and posttranslational modifications of histone deacetylase in macrophages. Am. J. Physiol. Lung. Cell Mol. Physiol. 291, L46-L57 (2006).
16. Wu, C. Chromatin remodeling and the control of gene expression. J. Biol. Chem. 272, 28171-28174 (1997).
17. Ito, K. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med. 352, 1967-1976 (2005).
18. Di Stefano, A. et al. Increased expression of nuclear factor-kappaB in bronchial biopsies from smokers and patients with COPD. Eur. Respir. J. 20, 556-563 (2002).
19. Ito, K. et al. Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J. Exp. Med. 203, 7-13 (2006).
20. Chen, J. Y. Antispasmodic activity of JB-340 (N-methyl-3- piperidyldiphenylglycolate methobromide) with special reference to its relative selective action on the sphincter of Oddi, colon and urinary bladder of the dog. Arch. Int. Pharmacodyn. Ther. 121, 78-84 (1959).
21. Buckley, J. P., De, F. J. &Reif, E. C. The comparative antispasmodic activity of N-methyl-3-piperidyl diphenylglycolate methobromide (JB-340) and atropine sulfate. J. Am. Pharm. Assoc. Am. Pharm. Assoc. (Baltim.) 46, 592-594 (1957).
22. Long, J. P. &Keasling, H. H. The comparative anticholinergic activity of a series of derivatives of 3-hydroxy piperidine. J. Am. Pharm. Assoc. Am. Pharm. Assoc. (Baltim.) 43, 616-619 (1954).
23. Tanaka, K. I., Sato, K., Aoshiba, K., Azuma, A. &Mizushima, T. Superiority of PC-SOD to other anti-COPD drugs for elastase-induced emphysema and alteration in lung mechanics and respiratory function in mice. Am. J. Physiol. Lung. Cell Mol. Physiol. 302, L1250-L1261 (2012).
24. Hanania, N. A. &Donohue, J. F. Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc. Am. Thorac. Soc. 4, 526-534 (2007).
25. Suzuki, M. et al. Down-regulated NF-E2-related factor 2 in pulmonary macrophages of aged smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Cell Mol. Biol. 39, 673-682 (2008).
26. Kundu, J. K. &Surh, Y. J. Nrf2-Keap1 signaling as a potential target for chemoprevention of inflammation-associated carcinogenesis. Pharm. Res. 27, 999-1013 (2010).
27. Mizushima, T. Drug discovery and development focusing on existing medicines: drug re-profiling strategy. J. Biochem. 149, 499-505 (2011).
28. Belmonte, K. E. Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2, 297-304 discussion 311-292 (2005).
29. Xue, H., Su, J., Sun, K., Xie, W. &Wang, H. Glutathione S-transferase M1 and T1 gene polymorphism and COPD risk in smokers: an updated analysis. Mol. Biol. Rep. 39, 5033-5042 (2012).
30. Gross, N. J., Giembycz, M. A. &Rennard, S. I. Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 7, 141-153 (2010).
31. Miravitlles, M. &Anzueto, A. Insights into interventions in managing COPD patients: lessons from the TORCH and UPLIFT studies. Int. J. Chron. Obstruct. Pulmon. Dis. 4, 185-201 (2009).
32. Tanaka, K., Sato, K., Aoshiba, K., Azuma, A. &Mizushima, T. Superiority of PC-SOD to other anti-COPD drugs for elastase-induced emphysema and alteration in lung mechanics and respiratory function in mice. Am. J. Physiol. Lung. Cell Mol. Physiol. 302, L1250-L1261 (2012).
33. Tanaka, K. et al. Therapeutic effect of lecithinized superoxide dismutase on pulmonary emphysema. J. Pharmacol. Exp. Ther. 338, 810-818 (2011).
34. Karakawa, T. et al. Applicability of new spin trap agent, 2- diphenylphosphinoyl-2-methyl-3,4-dihydro-2H-pyrrole N-oxide, in biological system. Biochem. Biophys. Res. Commun. 370, 93-97 (2008).
35. Griendling, K. K., Minieri, C. A., Ollerenshaw, J. D. &Alexander, R. W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74, 1141-1148 (1994).
36. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254 (1976).
37. Irizarry, R. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 4, 249-264 (2003).
38. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).